Loading...
2
0
20
0
false
Full Name
Sabri, Nagwa
Type
Subject
- 1 BAP1 mutations | Circulating tumor cells | Immunohistochemistry | Malignant pleural mesothelioma | Overall clinical benefit | Overall survival | Progression free survival
- 1 BDNF-TrkB-CREB signaling pathway | CoQ10 | Phenytoin | Vascular endothelial growth factor (VEGF) | α-Toc
- 1 Bioequivalence | Chronopharmacology | Circadian rhythm | Diabetes Mellitus | Empagliflozin 10 mg | Evening dose | Morning dose | Pharmacodynamic | Pharmacokinetics
- 1 biopharmaceutical classification system | critical micellar concentration | cyclodextrin | doxorubicin | nanomedicine | polyethylacrylate | Polymeric micelles
- 1 Breast cancer | Clinical pharmacist interventions | Quality of life | Toxicity grades
- 1 CABG | IL-6 | Ischemia/reperfusion injury | Melatonin | NF-kB | TNF-α | Troponins
- 1 Cannabis | Cytochrome P3A4 | Drug interactions | Erectile dysfunction | Oxidative stress | Pharmacodynamics | Pharmacokinetics | Safety | Sildenafil | Smokers
- 1 Cardiovascular disease risk | Daflon® | Diabetes mellitus
- 1 children | endothelial dysfunction | hemodialysis | inflammation | ramipril
- 1 Chronic hepatitis C | Sofosbuvir/daclatasvir | Statins
- < previous next >
Date issued
- 75 2000 - 2998
Fulltext
- 56 No Fulltext
- 19 With Fulltext
Results 61-75 of 75 (Search time: 0.0 seconds).